StudyFinder

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-DOSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VDPHL01 IN MALE SUBJECTS WITH ANDROGENETIC ALOPECIA

Status: Recruiting

The research study will compare VDPHL01 with placebo (no active ingredient) to learn about the safety and how VDPHL01 works for men who have androgenetic alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens resulting in hair loss. VDPHL01 is an extended release (ER) oral (taken by mouth) form of minoxidil.

I'm interested

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• male (based on sex at birth) - 18-65 years of age (inclusive)
• clinical diagnosis of mild to moderate Androgenetic Alopecia (AGA 0
Exclusion Criteria:

• uncontrolled high blood pressure
• history of heart disease
Interventions:

Drug: Placebo, Drug: VDPHL01

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

AGA, androgenetic alopecia, Men's hair loss

Study Contact: John Meisenheimer - jmeisenh@umn.edu
Principal Investigator: Maria Hordinsky
Phase: PHASE2
IRB Number: STUDY00024357
See this study on ClinicalTrials.gov

Back